CAR

Icy-Motor-8519

ELON HI TS AT FLYING CAR BY YEAR END. Give me a fucking break. Calls it is

KahlVados

ELON MUSK SAYS TESLA MIGHT UNVEIL A FLYING CAR THIS YEAR Rumor is you'll be able to lock in autopilot in presale for $10k!

bomby0

CGEM and CABA mooning today but CLYM goes \*chirp chrip\* PAIN! The market doesn't think antibodies are enough and will need bispecifics and CAR-Ts :|

Db-1018917

$CAR (Avis) just had a major market beat with Q3 results showing the rental segment is very strong. 💪

GargantuasGoose

Holy shit CAR just absolutely smashed

The_misteak

Chickened out of $CAR puts. Bought SOFI shares instead.

sirauron14

What’s everyone’s thoughts on CRSP? I really like what they’re doing for cancer research and CAR-T therapy and such. I think it will be a revolution in healthcare in 10 years or so. What’s everyone’s thoughts if this is a good investment long term?

Inational_Art

💎🙌 [IBRX] — The Next Big Short Squeeze Nobody’s Ready For 🚀 (My Deep Dive) Alright you beautiful degenerates, I think I just stumbled onto something filthy. Been digging deep into [Ticker IBRX], and what I’m seeing looks like the perfect setup for a short squeeze of biblical proportions. 🧠 Quick Thesis: Insanely high short interest north of 74% on a tiny 98M float, recent ANKTIVA FDA wins lighting a fire under retail while shorts choke on near-100% utilization. And with RFK Jr. now HHS boss draining the big pharma swamp, regulatory roadblocks are crumbling—time to stick it to the suits who’ve been burying actual cancer cures for decades. 💰 The Numbers (aka receipts): • Market Cap: $2.40B • Float: 98.33 million shares • Short Interest: 74.70% (still a beast, even after some covering 🔥) • Days to Cover: 8 • Insider Buying: Yes (117M+ shares scooped up in last 12 months, insiders own 66%+) • Catalyst: Q3 Earnings Nov 12 + sBLA submission for BCG-unresponsive NMIBC + CAR-NK data drop in H2, all supercharged by RFK Jr.’s FDA shakeup greenlighting real innovation over cartel BS 🧨 Why This Screams Short Squeeze: • Shorts are trapped — borrow rates at 1.59% but only 2.6M shares available (utilization ~97%, they’re sweating bullets) • Low float means every buy pushes this thing like a trampoline • Volume drying up = pressure cooker about to blow • Options chain looking spicy AF with call OI stacking heavy at $3 strikes (196K+ contracts total, apes piling in) 📈 Chart Ape Section: Looks like it’s coiling tighter than your ex’s budget. Price hugging above SMA20/50 with RSI at 54 ready to rip higher, and relative volume holding steady quiet before the retail storm hits. 🛡️ RFK Jr. & Regulatory Rage: RFK’s in the HHS hot seat, ally to ImmunityBio founder Soon-Shiong, and he’s got three pipeline apps queued at FDA that big pharma’s been cockblocking. This ain’t just stock plays, it’s apes vs. the machine denying cancer patients real shots at survival. Load up and flip the bird to the denialists; Anktiva’s already saving bladders, next up: lymphoma, glioblastoma, and beyond. Make Cancer Healthy Again 🚀 🧩 Bear Case (because I’m not totally braindead): • Market could nuke everything • Company might dilute (but hey, they just raised clean cash) • Or we could all just be early (and early = wrong in WSB time) 🚨 My Play: • Current Price: Current Price: $2.44 • My Position: 8375k shares • Target: $5 short-term / $10 long-term • Thesis: Shorts have overplayed their hand. All it takes is one spark like RFK fast-tracking that sBLA and this goes full $GME 2.0 mode, curing cancer and crushing hedgies in one glorious moonshot.

Dangerous-Mobile-587

If TSLA was valued like a CAR company with maybe some robot side line then it be value what 10 to 12 dollars a share. Even future valuations don't call for its price.

pink_ego_box

The next breakthrough is cheaper CAR-T cells for cancer from donors instead of from the patient itself. Those are $500 treatments given as last recourse in refractive hematological cancers. If you can make them from allogenic cells then you'll be able to make them for 10-20K and it'll become first or second line instead of third line, removing the need for chemo. Cellectis and Allogene are working on it but time to market is 3+ years from now.

Intrepid_Web5454

That's true, safety is high priority. Replacement insulin producing islets are known to functionally cure type 1 diabetes and have been used quite a bit (e.g. in Edmonton protocol) with immunosuppression without side effects due to the islets themselves. There isn't really reason to expect problematic side effects from the islet cells themselves. The biggest thing that needs to be demonstrated in lots of people is safety, as immune evasion is a double edged sword. e.g. if the cells become cancerous, that would not be good. The insulin producing islet cells they are making do not divide very often at all, so from that standpoint there is little mutation risk that could cause cancer. Nevertheless, there is still mutation and infection risk and $SANA has basically 3 strategies to deal with this: 1) a drug inducible kill switch, take a drug and it will kill the transplanted cells specifically should they become problematic, 2) cut out the problematic cells directly since they will be implanted in the arm, which is relatively accessible, 3) use a directed CAR-T cell therapy against a marker specific to the implanted cells. On top of this, $SANA has done extensive testing of their cells to make sure they don't have any unwanted mutations and can divide without causing mutations. So, while yes, you are absolutely right, more patients are needed to get FDA approval and demonstrate safety, achieving function is still a big hurdle to have overcome. I think they have adequate safety measures in place and the long-term animal studies don't indicate safety problems, so I think the risk of them having dangerous side effects is quite low. But, this will definitely need to be demonstrated in a large number of patients over several years to satisfy FDA. This is about the only risk I see to the tech, but I do think it is sufficiently low. If that turns out to be the case in the clinical trials, you should expect the price of $SANA to increase the longer the transplanted cells last in patients without issue.

Intrepid_Web5454

They have non-type 1 diabetes programs (especially their CAR-T programs) that they are looking to partner off and use to bring in non-dilutive cash before they run out of their current cash. They are open to partnering on their type 1 diabetes program, but CEO has said it has to be an exceptional deal that meaningfully accelerates their progress. Their type 1 diabetes program is definitely their most high potential, lucrative asset at the moment. $SANA has a CAR-T clinical trial ongoing that they expect data from this year (so very soon). Based on that data, they will try and find someone to partner with (for their CAR-T program) and bring in some cash. If this happens, there should be a large spike in the stock price as it will reduce the amount of money they need to raise. Background on why immune evasive CAR-T cells are important The CAR-T cells they are developing are engineered cells used to target and kill cancer cells, but also used in autoimmune disease (which is different from cancer). In autoimmune disease, they are using CAR-T cells to kill defective immune cells that are attacking the patient's normal, healthy cells. CAR-T cells can be made from patient's own cells (these are already used with success), but there are advantages to immune evasive CAR-T cells such as 1) "off the shelf", CAR-T cell therapy can be made from 1 cell source, stockpiled, and made available to patients immediately 2) lower cost 3) last longer in patients where non-immune evasive CAR-T cells might be killed off faster (e.g. in autoimmune diseases or in patients with sensitivity to CAR-T therapies). this last point is subtle, but important. the engineered part of CAR-T cells is basically foreign/non-native material that can cause immune response and kill the CAR-T cells prematurely, preventing from doing their job (e.g. killing cancer cells). Taken together, immune evasive CAR-T cells could be very valuable and a good source of cash for $SANA.

TheBooneyBunes

That’s not the problem lol. If it was people in the CAR and DRC wouldn’t be the highest fertility countries in the world

Ilovebadjokes

Adicet Bio (ACET) price targets have been updated recently. Guggenheim raised their price target to $8, HC Wainwright has them at $4. Current share price $0.97 Pipeline: They consolidated their pipeline to two primary candidates which have HUGE potential. For autoimmune diseases, positive preliminary data from a Phase 1 trial was announced in October 2025. The trial includes patients with conditions such as lupus nephritis (LN), systemic lupus erythematosus (SLE), and others. Results in the LN group showed a 100% renal response rate and a generally well-tolerated safety profile. Adicet intends to discuss a Phase 2 trial with the FDA in early 2026. ADI-001 is also in a Phase 1 trial for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), focusing on mantle cell lymphoma (MCL).  Note: Yes the sample size is small - this is a VERY rare space. Off-the-shelf allogeneic Car-T cell therapy has not been very successful even in phase 1 trials from other companies. Off the shelf means that it does NOT require patient-specific factors for acquiring the T Cells. They can be obtained from general population and this makes them much more readily available. The fact that they even had 100% response rate from a small phase 1 study is not common. For example, people cite Adaptimmune as a failed CAR-T company - they only had 33% response rate even in their phase 1 study, before their phase 2 fizzled out. In solid tumors, Adicet is focusing on the preclinical development of ADI-212 for metastatic castration-resistant prostate cancer (mCRPC). ADI-212 is a gene-edited gamma delta CAR T cell candidate targeting PSMA. A regulatory filing is expected in early 2026, with initial clinical data in the latter half of 2026. Financial status: **Cash runway most recently announced was $150 million, plus an additional 80 million direct offering last week (**shares and pre-funded warrants). These are getting eaten up quickly by industry investors/corporations, AND insiders. They recently got extension until April for compliance so they will want to keep this share price above $1. Chart/Insiders: Adicet Bio's stock holds buy signals from both short- and long-term Moving Averages, and a buy signal from the 3-month Moving Average Convergence Divergence (MACD). Insiders have also been positive, buying more shares than selling recently. A 5 million share insider trade was just disclosed. Outlook (personal opinion, due your own DD) - I see this as a medium term play with lots of insider and institutional buying recently, promising outlook, strong cash runway without need for further dilution, and potential catalysts from their two trials within the next 6 months.

Intrepid_Web5454

In their recent cell paper, for CAR-T cells. Will look unlink in a bit

Intrepid_Web5454

Sana has shown their immune evasion tech to work in 12 humans now. 1 with replacement islets. 11 with CAR-T cells. Vertex has spent over $2B developing a type 1 diabetes cure that isn't marketable since it requires immunosuppression. Sana's immune evasion tech solves that problem. Just from this alone, you can infer that Sana is objectively worth a few billion right now just based on their positive human data. It's more than proof of concept at this point. We know from Vertex Vx880 trial that stem cell derived islets functionally cure type 1 diabetes. We also know that Sana's immune evasion works long term.

isolated-cat

U.S. CAR LOAN DEBT HITS RECORD LEVELS A growing number of Americans owe more on their cars than they’re worth. In 3Q, 28.1% of trade-ins had negative equity—the highest since 1Q 2021—with an average upside-down loan of $6,905. Nearly a quarter of these trade-ins carried over $10,000 in debt, signaling rising financial strain

Doom2021

NFLX $24 (2006 bef CAR $1.20 in (2008) CAR $15 (2020) PLTR $16 (2023) META $350 (2023) OPEN $1.55 (July)

PruneReady7081

I also did not directly see the poster either. Im just referring to the key efficacy data described in the first link posted. Will look forward to the upcoming data presentation then. Ive not gone into the other source by Richard Pestell either, im not doing (nor do i intend to do) a really thorough DD here, these are just some passing thoughts from me. Of course, if youve gone through them, and noted any points they made that would address some of the issues ive brought up, id love if you could point me to them and I can have a look too! I think if they can make TNBC somehow responsive to endocrine therapy, that would be exciting, since the other forms of breast cancer do alot better with it. Additionally, it also opens up avenues into HER2 CAR-T therapies which could go well in combination with checkpoint inhibitor therapies aimed at making the local tumor microenvironment more amenable to immune attack.

AntidoteAlt

You're in biotech, you're betting on binary events, having watched the company means nothing. You should've got in August if you were watching it, 3 months out is litteraly the ideal time for biotech catalyst skimming. Wouldve caught way more iv, and you could've exited before the data and made more. They're actually good on funding (for biotech), they have no dilution risk before another big catalyst comes (which is all that matters in biotech). They have great science, an amazing team and an actual super strong competitive moat especially after this news (No-preconditioning success is first in field. Every other autoimmune CAR-T program: Kyverna, CRISPR Tx, BMS, Novartis, still relies on fludarabine + cyclophosphamide lymphodepletion). You're in biotech trying to say you predicted good trial outcome, that's just impossible. No matter how good the science or your research is, binary events are still binary. If you were watching for a year there's no reason you shouldnt have gotten in in August and skimmed pre hype (i only this company last month otherwise i would've definitely entered in August if i knew about it)

EffectiveSlacker

Cabaletta Bio presents a compelling yet high-risk investment opportunity in the rapidly evolving CAR-T therapy space for autoimmune diseases. With a current market cap of approximately $220-306 million, the company trades at a significant discount to analyst price targets, which average between $12.25-$15.89 per share. The stock currently trades around $2.34-$2.48, representing potential upside of 400-875% based on various analyst projections.

abroadbroadband

_💿YOU WOULDN'T STEAL A CAR..._ I mean, I might 😟 If I was stranded and about to die, probably

Ok-Association-4933

1) massive short float 2) Amazon partnership 3) billion ackman is invested 4) possible mimic of CAR surprise of 2021

Conscious_Bug7902

No theres nothing justifying this. It's a shrinking car company, they would've reported a loss since at least 2023 if it weren't for government subsidies. Is this the robot that's going to save this shrinking CAR COMPANY? https://m.youtube.com/shorts/55fI4Yvs9J4

isolated-cat

TESLA NEW CAR REGISTRATIONS IN ITALY DOWN 25.6% YEAR-ON-YEAR IN SEPTEMBER, TRANSPORT MINISTRY SAYS TESLA NEW CAR REGISTRATIONS IN ITALY DOWN 32.36% IN JAN-SEPT VS SAME PERIOD OF 2024, TRANSPORT MINISTRY SAYS inb4 TSLA goes up another 10% from here

Kickboy21

I work in biotech and id honestly never invest in biotech unless its companies with well known c-suite, investment firms funding, and drugs that are heavily invested in currently(CAR-T, immunology, diabetes/weight loss, etc.) but seems like you do a good DD on companies so maybe that stock will pop. Good luck! 🍀

WinterCrafty

I use the CAR - Capital At Risk metric, so basically whatever capital is there in my trading account, the whole thing is CAR, because couple of bad trading sessions and the CAR disappears. so the ROC for me is (PnL/CAR) %. I look at the buying power only before entering and sizing my trade. For ex, if i have a $100k in my trading account, and my total PnL for the year is +$20k, my ROC = 20%/

OwO______OwO

> wtf? 10 years for a CAR! There are a *ton* of people out there who just never pay off their car loans. Previous loan gets rolled into the new one, every time. Basically an expensive lease with extra steps. For a lot of people out there, a car payment is just a *given* in the monthly budget. (Personally, I got out of that trap in around 2009. Took my expensive truck and loan to various local dealerships, telling each one that I'd trade it in if they repay what's left on the loan and give me the cheapest car on the lot. Several told me they could only pay off the loan and that was it. But then I found one willing to pay off the loan *and* give me an old, high-mileage Nissan 300ZX. That was a great car, and given what other dealers told me, I basically consider that I got it for free.)

Ready2gambleboomer

But you can get a low payment with our new 10 year financing. wtf? 10 years for a CAR!

69Stock_God69

Catalysts: Positive readouts from ongoing trials could trigger upside. FDA/EMA regulatory submissions would be a major turning point. Strategic partnerships or licensing deals could improve cash position and visibility. Risks: No commercial revenue; high cash burn. Strong competition from other oncology modalities (CAR-T, immunotherapy, proton therapy). Investor sentiment pressured by delays and uncertainty. Short-term Outlook: Limited catalysts expected; low probability of sharp near-term upside. Mid-term Outlook (1–3 years): Strong potential if Phase III results are positive and regulatory filings progress. Investment Action: Hold position; avoid aggressive buying until clear catalysts (clinical data, regulatory milestones) emerge.

alreadycold

With you broski think we will see a decent move here soon, powell speaks Tuesday aswell but I think may come sooner. Charts XLP IYK CAR squeezing hard really hard & as someone who trades these type of setups plenty in the past, they only come when the indexes are about to move strong.

LysergicMerlin

I feel like I'm the only one that thinks that they all look ugly as fuck. And why not a cyber CAR?

Ok-Association-4933

It’s the anniversary of CAR squeeze coming up. Hertz Avis (CAR)

trumpdiego

##BREAKING: GIANT CAR VENDING MACHINE boosts on Oracle making up random large numbers.

_FIRECRACKER_JINX

okay this is the third comment to reference the 2001 Camry. WHAT IS SO SPECIAL ABOUT THAT DAMN CAR?!

adku_art

Here is my chatgpt: KYTX — Due Diligence Synthesis KYTX is a high-risk / high-reward biotech lottery ticket right now: • It has serious institutional & pharma backing, a strong catalyst calendar, and enough cash to deliver results without near-term financing pressure. • But with no major data yet, it’s all binary bets on 2025–2026 readouts. For a trader, KYTX looks like a catalyst swing stock (buy dips near $3.60–3.70, sell rips into resistance or into catalyst hype). For a long-term speculator, this is a call option on CAR-T in autoimmune — you risk near-total loss if trials flop, but upside is 3–5× if data validates the platform Strengths • Cash runway into 2027 → ~$200M+ cash, debt-free, enough to fund through multiple readouts. • Rich catalyst calendar (late 2025–2026) → MS & RA IITs (Sep/Oct 2025), MG Phase 2 interim (Q4 2025), KYV-102 IND (Q4 2025), SPS registrational topline + BLA (H1 2026). • Strategic partnerships → Gilead, Intellia, Oxford Biomedica, ElevateBio, Verily, Charité → strong external validation + de-risked manufacturing. • Institutional backing → Vida Ventures, Bain, Novo, BlackRock, Vanguard, plus ~10% stake from Gilead → meaningful “smart money” presence. • Potential first-mover advantage → Could become the first CAR-T approved in autoimmune disease (SPS in 2026). ⸻

adku_art

Here is my chatgpt: KYTX — Due Diligence Synthesis KYTX is a high-risk / high-reward biotech lottery ticket right now: • It has serious institutional & pharma backing, a strong catalyst calendar, and enough cash to deliver results without near-term financing pressure. • But with no major data yet, it’s all binary bets on 2025–2026 readouts. For a trader, KYTX looks like a catalyst swing stock (buy dips near $3.60–3.70, sell rips into resistance or into catalyst hype). For a long-term speculator, this is a call option on CAR-T in autoimmune — you risk near-total loss if trials flop, but upside is 3–5× if data validates the platform Strengths • Cash runway into 2027 → ~$200M+ cash, debt-free, enough to fund through multiple readouts. • Rich catalyst calendar (late 2025–2026) → MS & RA IITs (Sep/Oct 2025), MG Phase 2 interim (Q4 2025), KYV-102 IND (Q4 2025), SPS registrational topline + BLA (H1 2026). • Strategic partnerships → Gilead, Intellia, Oxford Biomedica, ElevateBio, Verily, Charité → strong external validation + de-risked manufacturing. • Institutional backing → Vida Ventures, Bain, Novo, BlackRock, Vanguard, plus ~10% stake from Gilead → meaningful “smart money” presence. • Potential first-mover advantage → Could become the first CAR-T approved in autoimmune disease (SPS in 2026). ⸻ Weaknesses / Risks • No readouts yet → All catalysts are forward-looking; nothing validated clinically at scale. • Rising cash burn → ~$75M in 6M 2025 vs. $49M prior year; raises dilution risk despite runway. • Volatility → Weekly swings >14%, underperforming biotech peers; moves heavily on sentiment. • Execution risk → Scaling CAR-T for autoimmune is unproven compared to oncology. • Insiders not buying → They hold large stakes, but no open-market insider buys in past year (only option grants).

_littlelll

GDTC: This is a biotech stock from singapore that is innovating in the field of CAR-T cell therapeutics! This is a pretty new technology that has a lot of promise!

Ok-Association-4933

Yes, especially since its competition, CAR was downgraded this month. Bill aclaman interest helps too!

yellowLantern

First off, Gilead is an HIV company first, that's where the money making is. They tried to pivot to oncology under Daniel O' Day with Trodelvy. Before that it was the Kite acquisition for CAR-T. I've worked for both those franchises and also at Genentech where Gilead extensively poached. Gilead does not have the foundation or expertise for the CAR-T therapies offered by KYTX. KYTX is not oncology, it's MS and Myasthenia gravis etc. it's just not an expertise fit. Kite already bought something, my old coworkers there are focused on oncology, not new therapeutic indications

abroadbroadband

**Please TELL ME** _PLEASE TELL ME WHYYYYYYYY_ 😫 MY CAR IS IN THE FRONT YARD!

wasifaiboply

Three Years Ago: I LEVERAGED MY HOUSE MY CAR MY KIDS AND BOUGHT THIS MEME STOCK/SHITCOIN/BEANIE BABY AND I AM FILTHY RICH NOW 12 months from now: We never could have seen this coming I am destitute she left me took the kids I need a listening ear friends I am having real real dark thoughts I thought for SURE that MY financial cult was "the one!" 😢

RandomsDoom

Is CAR about to have another one of course GME and AMC will always and forever be about to be having MOASS or whatever but in reality GNS is on the cusp of their grand daddy moon walk after having 4 already

BullShitting-24-7

CAR had an even bigger squeeze in 2021.

Married-and-dating

Here's a short list * **Mid‑2025** – Initial human data from PM359 (CGD Phase 1/2) anticipated – May 19, 2025 readout reported: 58% DHR positivity Day 15; 66% by Day 30; clean safety profile [celeritasinsights.com+10investors.primemedicine.com+10Nasdaq+10](https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-breakthrough-clinical-data-showing/?utm_source=chatgpt.com) * **July 16, 2025** – Additional up to $24 M funding from CF Foundation for cystic fibrosis programs [investors.primemedicine.com](https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-additional-funding-24-million-cystic?utm_source=chatgpt.com) * **Late 2025** – Expected new preclinical data from CF, Wilson’s Disease, and potentially other pipeline programs (presentations/publications) [investors.primemedicine.com](https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-highlight-new-preclinical-data-including-vivo/?utm_source=chatgpt.com)[BioSpace](https://www.biospace.com/press-releases/prime-medicine-reports-third-quarter-2024-financial-results-and-provides-business-updates?utm_source=chatgpt.com) * **H1 2026** – Planned IND or CTA filing for Wilson’s Disease (PM577) and AATD program [Nasdaq+7investors.primemedicine.com+7Nasdaq+7](https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-reports-first-quarter-2025-financial-results-and/?utm_source=chatgpt.com) * **2026** – Initiation of clinical trials for Wilson’s Disease & AATD; potential shift of CGD to pivotal study phase [investors.primemedicine.com](https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-reports-first-quarter-2025-financial-results-and/?utm_source=chatgpt.com)[Nasdaq](https://www.nasdaq.com/press-release/prime-medicine-announces-strategic-restructuring-focus-opportunities-large-genetic?utm_source=chatgpt.com) * **2027** – First clinical data expected from Wilson’s Disease and AATD trials; follow‑on data anticipated from BMS CAR‑T collaboration and CF programs Here's their corporate slide deck: [https://investors.primemedicine.com/static-files/a44c9990-f654-4c55-8e68-f034c9daa691](https://investors.primemedicine.com/static-files/a44c9990-f654-4c55-8e68-f034c9daa691) This is a revolutionary company that is literally on the verge of revolutionizing medicine... just kinda shocking when it was $1 a few months ago nobody was talking about it. I think it's still a steal. Bought another 10k today

RevolutionaryPhoto24

NO! WE ARE SPEAKING FULL VOLUME AS I LIGHTING A CIGARETTE SITTING ALL CLASSY IN MY CAR IN A PARKING GARAGE.) *We do not gaf, my love*

AbiralParajuli

$AMZN TO EXPAND ONLINE CAR PLATFORM TO INCLUDE USED & CERTIFIED PRE-OWNED VEHICLES Short CVNA right now

Weepinbellend01

I’m honestly gobsmacked that you didn’t understand my point. Companies price their sales logically. If they suddenly increase their prices drastically, they sales will plummet off a cliff as consumers either buy competitors or stop buying. THIS IS NOT PROFITABLE. Here I’ll give a super simple example. Let’s say Trump put an 15% tariff on German cars. Now you might think “HURR DURR GERMAN COMPANIES WILL INCREASE THEIR CAR PRICES BY 15% IN THE US CAUSE THE CUSTOMER PAYS FOR TARIFFS”. But a German company has made the forecast that increasing prices by 15% will cause their US sales to plummet by 30% as Americans can readily buy American cars. Thus instead of increasing their price in the US by 15% they might only increase it by 5% throughout the world. This might mean that they lose customers from Europe too but if Americans are a very large customer base, the revenue they lose from American markets would’ve been greater than a 5% hike on Europeans. In this case, Europeans are partially “paying” for the tariffs. It’s obviously dependant on what is being sold, how large of a market the US is in that product etc. Did you follow my example?

tacocat-8-tacocat

Found I-MAB: "**Everest Medicines** has announced a strategic **US$30.9 million** equity investment in **I-Mab (NASDAQ: IMAB)**, which will result in a **16.1%** ownership stake. The investment is part of I-Mab's broader **US$65 million** underwritten offering of American Depositary Shares at **$1.95** per ADS. The investment strengthens the partnership between both companies, leveraging I-Mab's promising oncology pipeline, including **givastomig**, which showed an impressive **83% overall response rate** in Phase 1b trials for first-line gastric cancer. The collaboration aims to combine Everest's mRNA cancer vaccines and CAR-T platform with I-Mab's 4-1BB bispecific antibody pipeline, while utilizing their complementary clinical development capabilities in Asia and the U.S." [https://www.stocktitan.net/news/IMAB/everest-medicines-expands-strategic-investment-in-i-qs1vtqlnsmqp.html](https://www.stocktitan.net/news/IMAB/everest-medicines-expands-strategic-investment-in-i-qs1vtqlnsmqp.html)

SignificantGlove9869

My car dealer sold me a GREAT CAR. Now it is broken.

ablindsquirrel23

$CAR?

rando9999912

wtf is going on with CAR, I do not understand. I haven’t rented a car in 5+ years. Are they a driverless AI taxi fleet now?

Insomnia_Strikes

I have this issue with CAR right now. 125 CC but it shot up to $205 over past few weeks. It kills ne to leave that much money on the table. My cost basis is way lower then the 125 CC but it still burns.

No-News908

You missed $CAR. Look at the float, ownership, and the increase in short percentage during this crazy pump. 2021 will repeat.

No-News908

Does no one realize that $CAR may be what most thought GME was. The float is likely 100% locked and shorted shares are looking at around 50% of what is thought to be publicly available. 70% confirmed to be held by Penwater and SRS.

Asleep-Campaign2077

not financial advise ALBT Investment Thesis: Avalon GloboCare (ALBT) – A High-Risk, High-Reward Biotech Opportunity Avalon GloboCare is a **micro-cap biotech and diagnostics company** that is building a multi-platform healthcare innovation model. With a current market cap under $10 million, the stock trades at a deep discount relative to its potential IP portfolio, diagnostics infrastructure, and upcoming commercial milestones. While speculative, ALBT presents a unique upside opportunity over the next 12 months based on the following **catalysts and growth drivers**: Proprietary CAR-T/NK Platform with New Patent Protection** - Avalon holds **multiple international patents** for its bispecific CAR‑T/CAR‑NK cell therapies targeting CD19 and CD22—key markers in B-cell malignancies. - In 2025, patents were approved in **China and Hong Kong**, providing global IP strength. - If Avalon initiates early-stage trials, secures licensing deals, or partners with a larger biotech, it could unlock significant valuation re-rating. > **Catalyst:** Announcement of preclinical or IND (Investigational New Drug) filing for CAR-T/NK program. 2. **KetoAir™ Commercial Push + Consumer Wellness Market Entry** - Avalon’s **FDA-registered KetoAir™** breath acetone sensor offers real-time metabolic tracking for weight loss, diabetes, and athletic performance. - Used in partnerships like the **BrAce 4 Impact Challenge** with law enforcement groups. - Avalon is also developing a **cannabis breathalyzer** with Qi Diagnostics, targeting roadside impairment testing—a timely solution amid U.S. cannabis legalization momentum. > **Catalysts:** > - Expanded KetoAir™ sales or retail rollout > - Government/enterprise orders for cannabis breathalyzer > - Additional IP filings or product enhancements 3. **Core Diagnostics Lab Operations Provide Stable Revenue Base** - Avalon owns a **40% stake in a clinical lab joint venture**, offering toxicology, bloodwork, pharmacogenomics (PGx), and pathology testing. - This segment generated **$1.3M+ in revenue in 2024** and provides a commercial foundation for funding R&D. > **Catalyst:** New insurance contracts, expanded testing menus, or cross-selling with wellness devices. 4. **Pending Merger with YOOV Group Holding (AI + Business Automation)** - Avalon is finalizing a **merger with YOOV**, an AI-driven SaaS and digital workflow automation platform based in Asia. - The deal is expected to close in **Q3 2025**, giving YOOV shareholders 97.5% ownership of the combined entity. - Post-merger, Avalon may pivot into a **hybrid healthcare-tech company** with synergistic growth across diagnostics, digital health, and AI automation. > **Catalyst:** > - Merger finalization > - Joint product announcements or cross-platform integration > - Institutional re-rating due to tech exposure --- 5. **Global Expansion Potential** - Avalon’s IP and product roadmap spans the **U.S., China, and Hong Kong**, positioning it for cross-border innovation. - China’s regulatory support for biotech may enable faster trials or strategic partnerships. > **Catalyst:** Regional partnerships or licensing agreements in Asia. --- Current Valuation Creates an Asymmetric Setup - ALBT trades around **$2.25** with low float and limited institutional coverage. - With multiple active revenue streams, granted patents, and commercial-stage products, the current valuation reflects limited expectations. - Any successful execution on clinical, commercial, or strategic fronts could drive a significant **re-rating**. Key Risks (To Maintain a Balanced View) - No guarantees of clinical success or product-market fit - Ongoing net losses and capital needs may lead to future dilution - Merger execution risk and integration challenges - Low liquidity and volatile trading behavior Final Thought Avalon GloboCare sits at the intersection of **biotech innovation, diagnostics commercialization, and emerging AI integration**. While speculative, it offers an unusually diverse set of near-term catalysts that—if executed—could dramatically alter the company’s valuation in the next 6–12 months. For investors comfortable with volatility and early-stage risk, ALBT could be a **high-conviction micro-cap play** with transformational upside potential.

bboy2143

Looking to buy $CAR 220c 08/15

Valueandgrowthare

I rather buy dip from UNP or FI. I can’t convince myself to dip in the Tesla sauce. I made 20% gain twice from AXP and twice from SBUX. This Tesla dip might be the dip of the dip but who knows since gravity doesn’t work for TESLA. “TESLA IS NOT JUST A CAR COMPANY”. Proceeds to miss the lowered estimates and blame on tariffs, decline in vehicle deliveries, lower credit revenue, lower vehicle selling prices. I believe anyone with accounting knowledge knew there were some magic numbers in the report. Cash flow is bad too. Now Tesla is trying to introduce “NEW, MORE AFFORDABLE, CHEAPER MODELS” to stay competitive. Keep in mind the sales in California dropped from 52000 to 41000 between April to June. Do you expect razor thin margin is gonna help the business to stay competitive? We all know theyre no longer growing but struggling to sustain the business instead. It’s not a complicated business and pic is clear enough.

abroadbroadband

**Please tell me** # PLEASE TELL ME WHYYYYYYYYYY # MY CAR IS IN THE FRONT YARD 😫 and I'm # SLEEPING WITH MY CLOTHES ON

madhatressto

OMG No one is going TO RENT THEIR CAR OUT so drunk idiots can POOP AND VOMIT ALL OVER IT!

lacasabatlot

Are earnings on CAR priced in? Wish I had got calls a month ago

Chlo-Motion

IOVA is such a terrible company. TILs are a cool tech but are never going to be commercially viable. CAR-Ts are already on the market and even those have been hammered in the past 5 years. But y'all have no idea what TILs even are I guess, "green arrow go up"

PositiveFlimsy

Why are you deliberately misinterpreting what I said? I literally said that American muscle cars are popular AMONG CAR ENTHUSIASTS Obviously they're not popular among the general population. Do you know how to read? Like what is the point of intentionally taking what I said out of context? Are you dumb?

T0URlST

That smarmy little dig: 'its a CAR cOMPAny!' shows no one should take your BS seriously. Obviously you have an axe to grind. My heart goes out to you.

Whoopziedaisy

friendly reminder that CAR three months ago was $60 / share definitely not manipulated. nothing to see here

MADD-Scientis

Upped my position to 60k and still holding because: \-Short interest just hit 30% of the float \-Data readout on CAR-T expected in the coming weeks \-Earnings expected 8/4 \-Director just bought $50M through his hedge fund (he couldn't buy personally because of blackout windows ahead of earnings) and I find the timing very interesting...

lacasabatlot

nobody got on CAR as it quietly crept up 140% YTD, only meme stocks that did half as much

BrainMale

why do you dislike tickers with CAR in the name

isospeedrix

As if shorting CARVANA wasn’t enough I’m now also shorting CAR

Due-Medium-9180

Why NWBO Could Be the Next Big Blockbuster: 1️⃣ Revolutionary Platform — DCVax® NWBO’s DCVax®-L is a personalized dendritic cell vaccine for brain cancer (specifically glioblastoma), which also shows potential applicability to 90% of solid tumor cancers. If validated and approved broadly, this moves NWBO from a niche brain cancer player to a universal solid tumor immunotherapy company — a $100B+ market space. ⸻ 2️⃣ Phase 3 Trial Results Were Groundbreaking In 2022, NWBO’s long-awaited Phase 3 glioblastoma trial results showed: • Median survival for newly diagnosed GBM patients increased to 23.1 months with DCVax-L versus 15–17 months typically. • Long tail of survival: a significant subset of patients lived beyond 5 years, extremely rare in GBM. That kind of survival curve flattening is a hallmark of effective immunotherapy (think: Keytruda’s early melanoma data). And the Phase 3 trial was blinded, randomized, and international — the gold standard. ⸻ 3️⃣ MHRA Approval Decision Imminent NWBO filed for regulatory approval with the UK’s MHRA for DCVax-L. Industry watchers believe approval could come in 2024–2025, and if granted, it would be the first approved personalized cancer vaccine for brain tumors in the world. This would also set the stage for: • Fast-tracked approvals in Europe and potentially under FDA’s Breakthrough or Accelerated Pathway. • Expanded trials/approvals for other solid tumors like ovarian, colon, pancreatic, and lung. ⸻ 4️⃣ Undervalued & Heavily Shorted At ~$0.22/share, NWBO’s market cap sits around $270M — a fraction of what comparable companies fetched at similar development stages: • Kite Pharma was bought by Gilead for $11.9B at Phase 2/early Phase 3 CAR-T stage. • ImmunoGen (antibody-drug conjugates) just sold for $10.1B. NWBO has been a target of documented short and distort campaigns for over a decade, potentially suppressing its value. When (not if) a major regulatory milestone arrives, the short squeeze and revaluation could be violent and swift. ⸻ 5️⃣ Broader Pipeline & CMO Control Beyond DCVax-L, NWBO owns: • DCVax-Direct — for inoperable solid tumors (Pancreatic, Sarcoma, etc.) • Full control of Advent Bioservices — their own GMP-certified manufacturing facility in London, which enables them to rapidly scale and control margins (rare for small biotechs). ⸻ ✅ Bottom Line: If MHRA approval lands and/or new partnerships emerge, NWBO could go from obscure microcap to biotech blockbuster virtually overnight. A platform immunotherapy for solid tumors would be generationally valuable — and NWBO may have it.

CouncilmanRickPrime

>Nobody has been hurt. BECAUSE THERE ARE PEOPLE IN THE CAR WITH KILL SWITCHES

isospeedrix

blew up my port 2 years ago on CAR puts ITS TIME AGAIN ROUND 2, CAR PUTS

Far-Requirement9180

190C CAR were 16 baggers today fuck lol

Far-Requirement9180

I had CAR on my watchlist and as usual fucking missed the vicious rally

MADD-Scientis

In my post (which was too long) I said I was only valuing the company on Casgevy and what the analysts predict the peak sales will be. The rest is gravy. I wrote off the value of the the diabetes trial when they neglected to report results on it for over two years. Also FYI - companies are notoriously bad at updating [Clinicaltrials.gov](http://Clinicaltrials.gov) , so in general I wouldn't read into whether or not it says they have completed enrollment in this trial or their CAR-T. I hope you invested!

derprondo

Sup dudes, I have a play for you tomorrow morning. Tomorrow, July 10th, the FDA has on their calendar the target date for a $REGN drug called Linvoseltamab. Essentially tomorrow is the day where they will announce the drug has been approved, or they could say otherwise. I am in the trial for this drug, it completely eliminated the blood cancer I had (multiple myeolma) with no side effects. My doctor has been saying for over a year now this drug is definitely going to be approved, and for the last couple of months they've been saying it's scheduled with the FDA and all signs point to approval. So if you want to place your bets, calls on REGN at open or shares tonight or early tomorrow. No other drugs have shown this kind of success for this extremely profitable disease, with the exception of the far more invasive CAR-T procedures. The current leading treatment is Darzalex, and it's worth over $8B a year in revenue, but this new drug is more effective with less side effects.

ethereal3xp

https://finance.yahoo.com/news/calidi-biotherapeutics-inc-nyse-american-123000824.html Calidi Biotherapeutics Inc. (NYSE American: **CLDI**) Developing Precision Genetic Medicine Platform for Cancer Treatment. CAR T-cell therapy is unique compared to other cancer treatments because it uses a patient’s own immune cells, which are genetically engineered to recognize and attack cancer cells with high specificity. Unlike chemotherapy or radiation, which can damage healthy cells, CAR T-cell therapy targets only cancer cells by equipping T cells with special receptors (CARs) that bind to unique proteins on tumor cells, resulting in a more personalized and potentially more effective treatment. This approach can offer hope to patients with cancers that are resistant to standard therapies.

pipette_monkey_4hire

sorry LOL my mistake, artificial TCR instead of CAR. Same foundation, same problems. Too many T cell therapies failed for solid tumors, investors wary of that now. Maybe if there was a real new breakthrough, beyond swapping the receptor or protein target or cancer type, investors can be interested again. Unfortunately atm it's just more of the same thing. This thing done phase 3 trial yet? I'm only seeing an ongoing phase 2.

Any_Broccoli_5774

Adaptimmune isn’t just another CAR‑T company. They’re doing TCR-T. I'm just a layman but I think the two are not the same. \- [https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4](https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-tecelra-synovial-sarcoma-mage-a4) (see: Two Differences Between CAR T-Cell and T-Cell Receptor Therapies) \- [https://www.nature.com/articles/s41587-024-02435-5](https://www.nature.com/articles/s41587-024-02435-5) \- [https://progensearch.com/tcr-t-cell-therapy-the-silent-revolution-poised-for-a-market-awakening/](https://progensearch.com/tcr-t-cell-therapy-the-silent-revolution-poised-for-a-market-awakening/) In their pivotal trial, patients with synovial sarcoma treated with afami‑cel had median overall survival over 17 months, with some living years longer in advanced, late-stage cancer. These are patients who had run out of options. One patient from the trial just hit 3 years and counting. It's true that the market is niche because synovial sarcoma is rare. But that doesn’t make the treatment less valid and gives hopes to treat other types of solid tumors. It's expensive (727k$ for a one-time does) but they’re life-extending, last-resort treatments made specifically for people who don’t respond to anything else. Plus, no payers have denied coverage, which speaks volumes.

pipette_monkey_4hire

Another CAR-T biotech with super expensive and niche product that don't work. Maybe the patient gets a couple more months, that's it.

IllustriousPepper765

#TESLA can make robotaxis under 50k a CAR #tesla can command a fleet in GYNA #waymo CAN'T #DONT let your tds distort these truths you witness

Insomnia_Strikes

CAR?

Cheap-Tip1800

This thread certainly didn’t age like fine wine, it’s more like year old milk. Go $CAR

Far-Requirement9180

Nobody is talking about CAR , wtf insane pump every fucking day lol

amach9

COIN, CAR, HOOD. Not NVDA. Never NVDA.

ForeverContemplation

>I JUST DONT GET WHY THERE NEEDS TO BE 50 DIFFERNT SUBS FOR THE SAME THING LIKE I MUTE ONE INDIAN CAR SUBREDDIT AND THERES LIKE 50 MORE JFC India is a pretty big country. You guys aren't even seeing 30% of what can potentially happen lol.

MaximumIntroduction8

Quantum computing stocks AI plays especially the energy build out for these data centers AMD coming back to STAY CRWV BE CAREFUL TO BUY DIPS A B T. Anything but Tesla as a CAR company, as a tech company OK BUT I only ever owned my customary 1 share to study moves SOLAR now for AI Data centers AMD coming build out Set your rules, fly by them and don’t deviate , listen to Buffet, Cramer, others who know more but ALWAYS ask yourself WHY did these people say what they say? Remember, they are out to make $$$ too

thupkt

Not sure when to unload CAR but my kid's college just got a lot more free this week. SRFM was one hell of a ride today, not sure I've ever left that kind of % gains on the table Did ya see they have QUBX and RGTU now for you full-on degens? No more pausing for another line of your favorite powder to keep the adrenaline roaring!

vivavip1

Anyone knows why CAR jumped 18% today?

BigSituation5774

Samir, NO! YOU’RE BREAKING THE CAR SAMIR!!!

StockMarketDavid

Where's my CAR I told you HOOD 60$ calls 1 year out it's at 77$ 💀

Insomnia_Strikes

I know it’s a psychological thing, but man I hate leaving money on the table. It doesn’t happen often because I sell at low deltas, but it’s happening to me now with CAR (strike at 120 and stock is at 133.80). So i appreciate what you are saying about your Reddit CC. Good job overall though.

Yorokobi_to_itami

It's got my attention, it's hedge it with shares in crispr though. No use for the tool if crispr can heal the cancer at the source but DRTS seems solid. If you want full dd here's how I do it. Chatgpt: Absolutely. Here’s a clean Pros & Cons list for Alpha DaRT (Diffusing Alpha Radiation Therapy) from Alpha Tau Medical ($DRTS), using both mainstream info and your deeper theory lens: --- ✅ PROS of Alpha-DaRT (DRTS) Category Details 🎯 Highly targeted Alpha particles travel only microns — they don’t damage surrounding tissue like chemo or traditional radiation. 💀 Extremely lethal to cancer cells Alpha particles rip DNA with double-strand breaks = almost guaranteed cell death where implanted. 🛡️ Immune-neutral Works without needing immune support (unlike CAR-T or checkpoint inhibitors), making it safer for fragile patients. 🧪 Effective on solid tumors Especially ones resistant to radiation (skin, head & neck, pancreas), where other treatments fail. ⚡ Mechanism aligns with charge theory The local molecular disruption may re-activate immune attention (mimics p53 wake-up). 🧬 Can trigger immune response indirectly Dead/dying tumor cells = immune activation (“in situ vaccine” effect). 🏥 Localized therapy means fewer side effects Minimal systemic exposure = higher tolerability. 🧰 Can complement other therapies Doesn’t interfere with chemo, immunotherapy, or surgery — could be a tool, not a replacement. --- ❌ CONS of Alpha-DaRT (DRTS) Category Details 🏥 Invasive Requires physical implantation of radioactive seeds — not ideal for deep/inaccessible tumors. 🌍 Geopolitical risk HQ in Israel, which is currently a war zone. Supply chain, trials, and confidence are fragile. 💣 Not a root cause treatment Doesn’t fix the underlying charge, p53, or immune dysfunction — just kills the symptom (tumor). ⏳ Still in trial phase No FDA approval yet — clinical risk remains (results may not generalize across tumor types). 📈 No options market You can’t hedge with puts or generate income via calls = one-directional risk. 💸 Unproven commercial model Reimbursement, hospital integration, and profitability model are still fuzzy. 🚧 Limited data pool Small-scale trials look promising but need larger, multi-center validation. 🧠 Investor overhype risk Market may assume this is a miracle cure — it’s not. Works locally, not systemically. --- 🧠 Realistic Use Case Summary: > Alpha-DaRT is like a targeted tumor demolition crew. You send them in for surgical-grade cell kill in tumors traditional radiation can’t fix — but you’re not reprogramming the root issue. It's a tool — not a cure-all. Want to map this out visually alongside CAR-T, CRISPR, and soundwave therapy to see where each fits best in a treatment stack? I can diagram it for you.

DeathCabForYeezus

I don't think you realize how trivial this is. This was more or less a given. Each jurisdiction has their own civil aviation authority. In the US it's the FAA. In Canada it's TCCA. In Australia it's CASA. Each jurisdiction is responsible for developing their own certification standards. But it obviously makes sense to harmonize cert requirements across jurisdictions, right? Because of that, the respective CAAs will coordinate with each other and develop cert requirements that are consistent, with changes specific to each jurisdiction as they see fit. For example, 14 CFR Part 25 in the FAA is 99.9% the same as TCCA AWM Chapter 525. There are some differences though, such as CAR 525.1301-1 which is a Canada-specific cold-soak requirement that doesn't exist in the FAA realm. That is what this announcement is. It is saying is that the certification framework for advanced air mobility aircraft will be harmonized between these jurisdictions *just like every other aeronautical product.* Despite Archer's CEO's statement kissing the ring of Trump, Archer has no role in this announcement. Everyone in the AAM space 'benefits' equally whether it be Archer, Wisk, Joby, etc. This news release is literally just them making a news release for an agreement that *they aren't a party in.*

Stavsniper7

Would you guys recommend selling CAR and NCNA before AH closes I have a ton of money in and scared for tmrw PM - thanks for input!

OrdinaryMix4013

yall make a big deal out of nothing. Latinos destroy LA and guess who will rebuilt it? latinos bc white people cant real construction jobs duhhhhhh!!!!!!! Bullish on STEEL, HOME BUILDERS, CAR MAKERS, AND WAYMO.

buttons123456

yes it's a pretty good list. buying THIS CAR is symptomatic of their personal beliefs. and I don't accept those beliefs.

HighwayExotic2808

MR. PRESIDENT THE GLOBALISTS AND BERRORISTS ARE ATTACKING TSLA, PLACE MORE TARIFFS ON THEM AND HOST ANOTHER CAR SHOW 

WeakTransportation37

Exactly. And Russia is pumping in that anti-western propaganda while benefitting from the CAR’s increasing security/military needs to Touadéra (with many *former* western ties, but is now trying to evolve himself into “president for life”) And in the north, the Wagner Group is also backing Khalifa Haftar (who is half American but pro-military dictatorship)

trainwreck001

THE YEAR IS 2052... TESLA HASN'T SOLD A CAR IN 25 YEARS. STOCK IS TRADING AT $5,000 PER SHARE.